In the last trading session, 1.62 million shares of the PTC Therapeutics Inc (NASDAQ:PTCT) were traded, and its beta was 0.50. Most recently the company’s share price was $47.86, and it changed around $1.93 or 4.20% from the last close, which brings the market valuation of the company to $3.79B. PTCT currently trades at a discount to its 52-week high of $58.38, offering almost -21.98% off that amount. The share price’s 52-week low was $28.72, which indicates that the current value has risen by an impressive 39.99% since then. We note from PTC Therapeutics Inc’s average daily trading volume that its 10-day average is 1.13 million shares, with the 3-month average coming to 1.21 million.
PTC Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.94. If we narrow it down even further, the data shows that 1 out of 18 analysts rate the stock as a Sell; another 3 rate it as Overweight. Among the rest, 6 recommended PTCT as a Hold, whereas 7 deemed it a Buy, and 1 rated it as Underweight.
PTC Therapeutics Inc (NASDAQ:PTCT) trade information
Instantly PTCT has showed a green trend with a performance of 4.20% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 49.12 on recent trading dayincreased the stock’s daily price by 2.57%. The company’s shares are currently up 6.03% year-to-date, but still up 1.92% over the last five days. On the other hand, PTC Therapeutics Inc (NASDAQ:PTCT) is -3.37% down in the 30-day period. We can see from the shorts that 5.01 million shares have been sold at a short interest cover period of 4.11 day(s).
The consensus price target as assigned by Wall Street analysts is $62, which translates to bulls needing to increase their stock price by 22.81% from its current value. Analyst projections state that PTCT is forecast to be at a low of $58 and a high of $66.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -2.04%. PTC Therapeutics Inc earnings are expected to increase by 263.45% in 2025, but the outlook is positive 55.77% per year for the next five years.
PTCT Dividends
PTC Therapeutics Inc’s next quarterly earnings report is expected to be released on 2025-May-05.
PTC Therapeutics Inc (NASDAQ:PTCT)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 2.42% of PTC Therapeutics Inc shares, and 100.98% of them are in the hands of institutional investors. The stock currently has a share float of 103.49%. PTC Therapeutics Inc stock is held by 371.0 institutions, with VANGUARD GROUP INC being the largest institutional investor. By 2024-06-30, it held 11.696% of the shares, which is about 8.97 million shares worth $274.42 million.
WELLINGTON MANAGEMENT GROUP LLP, with 10.6987% or 8.21 million shares worth $251.02 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund were the top two Mutual Funds as of Jan 31, 2025 . The former held 2.8 shares worth $133.85 million, making up 3.53% of all outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund held roughly 2.39 shares worth around $114.6 million, which represents about 3.02% of the total shares outstanding.
